Added to YB: 2026-02-06
Pitch date: 2026-02-04
NVO [neutral]
Novo Nordisk A/S
+1.7%
current return
Author Info
TacticzHazel is a Long-Term Investor with a Value Mindset - Self-taught Investor with a Focus on Quality Fundamental Analyses in every Corner of the Market. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 302.25
Price Target
N/A
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
N/A
Novo Nordisk - Emergency Update
NVO (earnings): Down 15% on surprise 2026 guidance cut (-5% to -13% sales/op profit vs +1/2% consensus). 5th cut in 12 months hurts credibility. Driven by US pricing pressures, semaglutide patent expiry, Lilly competition, FX headwinds. 2025 results decent: +6% sales, obesity +26%. Wegovy pill uptake strong at 170k patients. Holding position pending more clarity.
Read full article (4 min)